Automation Workflow for Preclinical Candidate Selection and Ranking

The final selection of a preclinical candidate is a high-cost, high-stakes decision bottleneck. Manual aggregation of data from disparate assays, predictive models, and electronic lab notebooks (ELNs) consumes weeks of project team effort and introduces risk through inconsistent scoring and incomplete data packages. Automating this gate standardizes the rubric, enforces data completeness, and creates a defensible audit trail for portfolio governance. The operational upside is a 60-80% reduction in committee preparation time and a more rigorous, data-driven selection process that reduces late-stage attrition risk.

Implementation requires orchestrating specialized agents for data aggregation from sources like Dotmatics or Benchling, applying multi-parameter optimization (MPO) scoring logic, and aligning results with portfolio strategy. The workflow is built on a framework like LangGraph, with human-in-the-loop approval gates integrated via Slack or Microsoft Teams. Critical controls include validation of data provenance, confidence scoring for predictive inputs, and immutable logging of all scoring rationale and committee decisions to satisfy internal and future regulatory scrutiny.

This workflow automates the high-stakes decision gate where a lead series is narrowed to a single preclinical candidate. It eliminates the manual, error-prone aggregation of data from disparate sources—ELNs, assay databases, ADMET predictions, and IP checks—into a unified dashboard. By applying portfolio-defined scoring rubrics automatically, it brings objective rigor to the selection process, reducing committee meeting time by weeks and creating a defensible, audit-ready record for internal governance and regulatory scrutiny.

Implementation integrates with core R&D systems: an orchestrator (LangGraph) manages specialized agents for data collection and Multi-Parameter Optimization (MPO) scoring. The workflow enforces data completeness checks before review, routes exceptions, and logs all rationale. The final architecture deploys as a containerized service, connecting to ELNs (e.g., Benchling), assay databases, and visualization tools like Spotfire, with role-based access controls governing each approval step in the collaborative review hub.

Phase 1 establishes the foundational data pipeline, automating the aggregation and standardization of assay results, ADMET predictions, and synthetic feasibility scores from disparate sources like ELNs, screening databases, and computational platforms. This initial orchestration layer, built with tools like LangGraph, creates a single source of truth and eliminates days of manual data wrangling per candidate series. The focus is on data integrity and building trust with the project team through transparent, auditable data flows before introducing automated scoring.

Phase 2 introduces the Multi-Parameter Optimization (MPO) scoring engine and collaborative review dashboard. Here, the business value is realized: the system applies portfolio-defined rubrics to rank candidates, reducing committee deliberation from weeks to days. Implementation requires careful governance—configurable scoring weights, human-in-the-loop approval gates, and immutable audit trails for regulatory defensibility. The final phase optimizes the system with model retraining pipelines and portfolio analytics, ensuring the workflow evolves with project data and supports strategic portfolio decisions.

This workflow automates the final, high-stakes decision gate where a lead series is narrowed to a single preclinical candidate. It replaces fragmented committee reviews and manual data aggregation with a structured orchestration layer that enforces portfolio-defined scoring rubrics. The operational upside comes from reducing candidate selection cycles from weeks to days, eliminating manual data-package assembly, and creating a transparent, auditable record for internal governance and regulatory scrutiny. Savings are realized through reduced scientist and committee labor and by de-risking the transition to costly GLP toxicology studies.

Implementation requires integrating with enterprise systems like an Electronic Lab Notebook (ELN), a Compound Data Management System (CDMS), and a document management platform. The orchestration layer, built with LangGraph, sequences specialized agents for ADMET, efficacy, and synthesizability scoring before applying a Multi-Parameter Optimization (MPO) algorithm. Critical controls include configurable approval thresholds, mandatory human review for borderline scores, and immutable audit logging of all agent reasoning and decisions. Rollout is phased, starting with a single project team to validate scoring logic and exception handling before scaling across the portfolio.

This workflow automates the critical, multi-disciplinary bottleneck of selecting a single preclinical candidate from a lead series. It replaces fragmented data reviews and subjective committee debates with a structured, auditable orchestration layer. The operational upside is measured in weeks saved from the development timeline, reduced risk of selecting suboptimal candidates, and the creation of a defensible data package for internal governance and regulatory inquiries. Implementation requires integrating data from ELNs, assay databases, ADMET prediction platforms, and IP systems into a centralized decision engine.

The architecture is built on an agentic orchestrator, like LangGraph, that sequences data aggregation, scoring, and governance tasks. Key controls include configurable scoring rubrics, mandatory data completeness checks, and electronic sign-off workflows within systems like Veeva or SharePoint. Exception handling routes incomplete data packages back to project teams. The final output is a ranked candidate list with supporting evidence, ready for synthesis and toxicology studies, dramatically reducing committee meeting time and manual report assembly.